Brief: Astellas Pharma Inc- Recording Of Extraordinary Losses In Non-Consolidated Financial Results
04/02/2025 23:33
Feb 5 (Reuters) - Astellas Pharma Inc 4503.T :
* ASTELLAS PHARMA INC- RECORDING OF EXTRAORDINARY LOSSES IN
NON-CONSOLIDATED FINANCIAL RESULTS
* ASTELLAS PHARMA INC- RECORDED 60.6 BILLION YEN OF
EXTRAORDINARY
LOSSES IN NON-CONSOLIDATED FINANCIAL RESULTS DUE TO SIGNIFICANT
DECLINE IN VALUE OF SHARES OF SUBSIDIARY GANYMED
PHARMACEUTICALS GMBH
Source text: ID:nTSnd8974f
Further company coverage: 4503.T
(Reporting by Rocky Swift)
((rocky.swift@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsBrief: Immuneering To Collaborate With Astellas On Clinical Studies Of Investigational CLDN18.2 Programs In Combination With Atebimetinib For Pancreatic Cancer Patients
Health Rounds: New blood test finds early risk for ovarian cancer
Health Rounds: New blood test finds early risk for ovarian cancer
Refile: Astellas employee imprisoned in China to be released in December, Japanese media report
Table: Astellas Pharma -6-MTH group results (IFRS)